Datopotamab Deruxtecan, often abbreviated as DATO, represents a significant advancement in targeted cancer treatment. This innovative antibody-drug conjugate combines an monoclonal immunoglobulin specifically targeting https://bookmarklinking.com/story10927694/dato-deruxtecan-an-encouraging-adc-link